Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 14/20 | 0.49 |
| ▸ | HTR1A | P08908 | 13/20 | 0.49 |
| ▸ | HTR6 | P50406 | 4/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | HRH2 | P25021 | 2/20 | 0.44 |
| ▸ | HTR1B | P28222 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | HTR5A | P47898 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caldaret SCHEMBL3139412 | 0.98 | ALDH1A1 (0.51) | ALDH1A1HTR3AHTR1AHTR6ADRB1 | |
| Caldaret SCHEMBL3135751 | 0.98 | ALDH1A1 (0.51) | ALDH1A1HTR3AHTR1AHTR6ADRB1 | |
| Caldaret SCHEMBL2853338 | 0.98 | ALDH1A1 (0.51) | ALDH1A1HTR3AHTR1AHTR6ADRB1 | |
| Caldaret SCHEMBL29711318 | 0.98 | ALDH1A1 (0.51) | ALDH1A1HTR3AHTR1AHTR6ADRB1 | |
| Caldaret SCHEMBL3139464 | 0.91 | ALDH1A1 (0.45) | ALDH1A1HTR3AHTR1AHTR6ADRB1 | |
| SCHEMBL8636364 | 0.88 | HTR1A (0.49) | ALDH1A1HTR3AHTR1AHTR6ADRB1 | |
| SCHEMBL22542102 | 0.86 | ALDH1A1 (0.54) | ALDH1A1HTR3AHTR1AHTR6ADRB1 | |
| Caldaret SCHEMBL3139404 | 0.85 | ALDH1A1 (0.52) | ALDH1A1HTR3AHTR1AHTR6ADRB1 | |
| SCHEMBL4725678 | 0.84 | ALDH1A1 (0.51) | ALDH1A1HTR3AHTR1AHTR6ADRB1 | |
| SCHEMBL2852302 | 0.82 | USP2 (0.54) | HTR3AHTR1AHTR6ADRB1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007657-A1 | PHARMACEUTICAL COMPOSITION FOR KERATOSIS AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-01-08 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-7652017-B2 | Remedies and/or preventives for nervous system disorders | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-01-26 | — | — | US | claimed |
| EP-1062948-B1 | REMEDIES FOR NON CARDIOGENIC DIASTOLIC DYSFUNCTION | MITSUBISHI CHEM CORP (JP) | 2010-01-06 | — | — | EP | claimed |
| US-20090318461-A1 | CRYSTALLINE POLYMORPHISM OF 5-METHYL-2-(PIPERAZIN-1-YL) BENZENESULFONIC ACID | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-12-24 | — | — | US | claimed |
| CN-100502861-C | Medicament inhibiting sodium/calcium exchange system | MITSUBISHI PHARMA CORP (JP) | 2009-06-24 | — | — | CN | claimed |
| CN-100496495-C | Remedies and/or preventives for diabetic ischemic heart diseases | MITSUBISHI PHARMA CORP (JP) | 2009-06-10 | — | — | CN | claimed |
| CN-100486574-C | Remedies and/or preventives for nervous system disorders | MITSUBISHI PHARMACEUTICALS INC (JP) | 2009-05-13 | — | — | CN | claimed |
| EP-2050741-A1 | CRYSTALLINE POLYMORPHISM OF 5-METHYL-2-(PIPERAZIN-1-YL)BENZENESULFONIC ACID | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-04-22 | — | — | EP | claimed |
| EP-2048138-A1 | SALT OR SOLVATE OF 5-METHYL-2-(PIPERAZIN-1-YL)BENZENESULFONIC ACID | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-04-15 | — | — | EP | claimed |
| US-6407113-B1 | 2-(1-PIPERAZINYL)-5-METHYLBENZENESULFONIC ACID DERIVATIVE OR ITS SALT, OR HYDRATE OR SOLVATE; IMPROVE ABNORMAL INTRACELLULAR HANDLING CALCIUM ION | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-06-18 | — | — | US | claimed |
| US-20020028822-A1 | Medicament for treatment of diastolic dysfunction | KAWASUMI HISASHI (JP) | 2002-03-07 | — | — | US | claimed |
| US-6245767-B1 | CARDIOVASCUALR DISORDERS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-06-12 | — | — | US | claimed |
| EP-1062948-A1 | REMEDIES FOR CARDIAC DILASTOLIC DISORDERS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-12-27 | — | — | EP | claimed |
| EP-0779283-B1 | Monohydrates of aminobenzenesulfonic acid derivatives and method for preparation thereof | MITSUBISHI CHEM CORP (JP) | 2000-03-01 | — | — | EP | claimed |
| US-5990113-A | MONOHYDRATE OF 2-(1-PIPERAZINYL)-5-METHYLBENZENESULFONIC ACID, FREE OF ANHYDROUS CRYSTALS; FREE FROM WEIGHT CHANGE DUE TO MOISTURE ABSORPTION AND CAN BE WEIGHED ACCURATELY IN MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR HEART DISEASES | MITSUBISHI CHEMICAL CORPORATION (JP) | 1999-11-23 | — | — | US | claimed |
| EP-0779283-A1 | Monohydrates of aminobenzenesulfonic acid derivatives and method for preparation thereof | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-06-18 | — | — | EP | claimed |
| EP-0390654-B1 | Aminobenzenesulfonic acid derivative | MITSUBISHI CHEM IND (JP) | 1994-11-09 | — | — | EP | claimed |
| US-5053409-A | Calcium chanel blockers, antiischemic agent | MITSUBISHI KASEI CORPORATION (JP) | 1991-10-01 | — | — | US | claimed |
| EP-0390654-A1 | Aminobenzenesulfonic acid derivative | Mitsubishi Chemical Corporation (JP) | 1990-10-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007657-A1 | PHARMACEUTICAL COMPOSITION FOR KERATOSIS AND USE THEREOF | KRT18, PRKDC, DPM1 | ALDH1A1 686/4885HTR3A 3416/4885HTR1A 3791/4885 |
| US-20090318461-A1 | CRYSTALLINE POLYMORPHISM OF 5-METHYL-2-(PIPERAZIN-1-YL) BENZENESULFONIC ACID | KDM5C, KDM5A, NT5C3B | ALDH1A1 875/4885HTR3A 303/4885HTR1A 958/4885 |
| US-20020028822-A1 | Medicament for treatment of diastolic dysfunction | TNNI3, TNNT2, FABP3 | ALDH1A1 2695/4885HTR3A 1280/4885HTR1A 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.